<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04063501</url>
  </required_header>
  <id_info>
    <org_study_id>18-01845</org_study_id>
    <nct_id>NCT04063501</nct_id>
  </id_info>
  <brief_title>Longitudinal Evaluation of Microbial and Host Signatures During Immunotherapy for Lung Cancer</brief_title>
  <official_title>Longitudinal Evaluation of Microbial and Host Signatures During Immunotherapy for Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will prospectively collect airway, stool, and blood samples on 80 subjects with
      lung cancer undergoing immunotherapy. Investigators will evaluate airway/stool microbial
      signatures associated with local (lower airway) and systemic (blood) immune tone.They will
      then study whether microbiota and/or host signatures predict subjects' response by
      longitudinal assessment of the progression free survival. They will also repeat sampling
      after 8 weeks of immunotherapy to expand our mechanistic understanding of the response to
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>3 Years</time_frame>
    <description>over â‰¥ 1-year follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbiota signatures in lower and upper airways</measure>
    <time_frame>3 Years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbiota signatures in stool</measure>
    <time_frame>3 Years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Advanced stage unresectable Non-Small Cell Lung Cancer</arm_group_label>
    <description>Adult patients with a diagnosis of advanced stage unresectable Non-Small Cell Lung Cancer and indication for PD-1 blockade treatment (either as monotherapy or combined with chemotherapy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bronchoscopy</intervention_name>
    <description>The patient will then return within a week for a research bronchoscopy to sample the upper and lower airways</description>
    <arm_group_label>Advanced stage unresectable Non-Small Cell Lung Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Research Procedures</intervention_name>
    <description>electrocardiogram, blood work (CBC, chemistry, coagulation profile and liver function tests, pregnancy test if applicable), X-ray and pulmonary function (spirometry) testing, and provide the patient with a stool collection kit.</description>
    <arm_group_label>Advanced stage unresectable Non-Small Cell Lung Cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bacterial DNA will be extracted using an ion exchange column (Qiagen). Microbial DNA samples
      will potentially be further analyzed for relationships with underlying pathologies as well as
      to characterize in detail the genetic pool and genetic interactions..
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with a diagnosis of advanced stage unresectable Non-Small Cell Lung Cancer
        and indication for PD-1 blockade treatment (either as monotherapy or combined with
        chemotherapy)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with a diagnosis of advanced stage unresectable Non-Small Cell Lung
             Cancer and indication for PD-1 blockade treatment (either as monotherapy or combined
             with chemotherapy)

        Exclusion Criteria:

          -  Antibiotic, steroid, or chemotherapy received within the prior month since these are
             possible confounders that may impact the microbiome and the host immunity.

          -  Brain metastasis (as evaluated by MRI obtained as part of standard of care staging
             evaluation)

          -  FEV1&lt;50% predicted

          -  Cardiovascular disease (defined as abnormal EKG, known or suspected coronary artery
             disease or congestive heart failure)

          -  Renal disease

          -  Coagulopathy

          -  Liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leopoldo N Segal, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashley N Witzl</last_name>
    <phone>212-263-1208</phone>
    <email>Ashley.Witzl@nyulangone.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ashley N Witzl</last_name>
      <phone>212-263-1208</phone>
      <email>Ashley.Witzl@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Leopoldo Segal, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 19, 2019</study_first_submitted>
  <study_first_submitted_qc>August 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2019</study_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

